Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 11/20 | 0.49 |
| ▸ | BRD4 | O60885 | 7/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19489925 | 0.91 | BRD4 (0.52) | CREBBPBRD4PTGDR | |
| SCHEMBL19489833 | 0.91 | CREBBP (0.53) | CREBBPBRD4PTGDR | |
| SCHEMBL19460965 | 0.90 | CREBBP (0.47) | CREBBPBRD4PTGDR | |
| SCHEMBL19489837 | 0.90 | CREBBP (0.47) | CREBBPBRD4PTGDR | |
| SCHEMBL19490118 | 0.89 | BRD4 (0.46) | CREBBPBRD4PTGDR | |
| SCHEMBL19490183 | 0.88 | CREBBP (0.45) | CREBBPBRD4PTGDRADORA2A | |
| SCHEMBL19460479 | 0.88 | CREBBP (0.67) | CREBBPBRD4PTGDR | |
| SCHEMBL19489763 | 0.87 | BRD4 (0.49) | CREBBPBRD4PTGDRADORA2A | |
| SCHEMBL19489715 | 0.87 | BRD4 (0.47) | CREBBPBRD4PTGDRADORA2A | |
| SCHEMBL19490108 | 0.87 | CREBBP (0.52) | CREBBPBRD4PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | CREBBP 32/4885BRD4 5/4885PTGDR 2331/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | CREBBP 32/4885BRD4 5/4885PTGDR 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.